)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Revenio Group
Revenio Group (REG1V) investor relations material
Revenio Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 net sales rose 127.5% YoY to €58.8m, largely reflecting the Visionix acquisition; organic sales were flat and comparable pro forma sales declined 0.5%.
Integration advanced to plan, with 25% of the ~€20m synergy target completed; focus is shifting toward commercial synergies.
Financial highlights
Q3 adjusted EBITA was €8.7m, up 30.3%, with a 14.7% margin; adjusted EBITDA was €10.2m, up 38.9%.
Q3 reported EBIT was €3.6m versus €6.0m; profit was €3.4m versus €4.6m, and EPS was €0.116 versus €0.173.
9M sales were €125.4m, up 59.8%; adjusted EBITA was €21.7m, up 4.7%, and adjusted EBITDA was €24.9m, up 9.1%.
Q3 operating cash flow was €5.5m versus €3.0m, supported by working capital and reduced by €2.0m of integration payments; 9M operating cash flow was negative €0.3m.
Outlook and guidance
2026 currency-adjusted net sales guidance narrowed to €190m–€200m from €190m–€205m; adjusted EBITA margin is expected to remain satisfactory.
The lower end assumes continued soft demand and slower customer activity; the upper end depends on market improvement and successful commercial initiatives.
APAC weakness, North American sales reorganization effects and component cost pressures weigh on the outlook; ILLUME FDA approval timing shifted toward Q3–Q4 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Revenio Group
- €80 million rights issue supports Visionix integration, growth, and runs September 28–October 12, 2026.REG1V
Status update - Targeting 5%-10% sales CAGR and 25% EBITDA by 2029, driven by integration and innovation.REG1VCMD 2026
- Q2 net sales up 48.1% as Visionix boosted growth but pressured margins and leverage.REG1VQ2 2026
- Net sales rose 4.8% but profit dropped on Visionix costs; acquisition expands market reach.REG1VQ1 2026
- Merger forms a top global eye care leader, targeting EUR 20m+ synergies and rapid growth.REG1VM&A announcement
- 2025 net sales up 6% to EUR 109.7M, record cash flow, and 2026 sales growth expected at 8–15%.REG1VQ4 2025
- Q3 2025 saw strong sales and profitability, with 6–15% sales growth forecast for 2025.REG1VQ3 2025
- Q2 net sales up 14.2%, strong cash flow, and 2024 sales growth guidance of 5–10%.REG1VQ2 2024
- Record Q1 sales and profit, driven by global growth and strong financials.REG1VQ1 2025
Next Revenio Group earnings date
Q4 202611 Feb, 2027
Revenio Group
Next Revenio Group earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Revenio Group Oyj designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration. The company's vision is to create a world without blindness. It offers ophthalmology and optometry products like the Topcon Refractometer, the Diagnolyzer FT, the Diabetoscan DR/A1C+, and the XDM-400 Cell Health Analyzer; cell health analysis systems for measuring cellular health of skin cells, bone marrow cells and dental pulp cells; as well as other medical devices that measure the mechanical stress of tissues by stethoscopy (examination of tissues via a stethoscope) and laser Doppler flowmetry (measures blood flow in tissue), and enables quantitative analysis of renal function. The company is based in Vantaa, Finland.